You are here:
Idiopathic Pulmonary Fibrosis (IPF)
No estimate possible yet
Clinical trials
Zinpentraxin alfa
Lung diseases
New medicine (specialité)
Lung diseases other
Roche
Intravenous
Intravenous drip
Intermural (MSZ)
A recombinant form of human pentraxin-2 protein able to regulate monocytes and macrophages at areas of tissue damage to prevent and reverse fibrosis.
Centralised (EMA)
No
2024
2025
Yes
1 times every 4 weeks
10 mg/kg
NCT04594707, NCT04552899
< 2,040
Market share is generally not included unless otherwise stated.
Jaarverslag Longfibrosepatiëntenvereniging 2017 (1)
Er zijn ongeveer 3.400 longfibrose patiënten in Nederland 60% daarvan heeft IPF. Dit komt neer op 2.040 IPF patiënten.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
Phase II: Myelofibrosis
SPS UK
There is currently no futher information available.
Understanding of expected market entry of innovative medicines